MDXG240719P7500
- 0.60
- 0.000.00%
MiMedx Newsroom
Analyst Bullish On MiMedx's Rapid Growth In $4B Woundcare Market With Innovative Skin Substitutes
Cantor Fitzgerald has initiated coverage on MiMedx Group Inc. (NASDAQ:MDXG), a provider of a product portfolio for applications in wound care, burn, and surgical recovery.The analyst notes that MIMEDX
Cantor Starts MiMedx at Overweight, Cites Valuation, Product Offerings
MiMedx Group Initiated at Overweight by Cantor Fitzgerald
MiMedx Group Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Initiates MiMedx(MDXG.US) With Buy Rating, Announces Target Price $11
Cantor Fitzgerald analyst Ross Osborn initiates coverage on $MiMedx(MDXG.US)$ with a buy rating, and sets the target price at $11.According to TipRanks data, the analyst has a success rate of 18.1% an
Express News | MiMedx Announces the Appointment of Kim Moller to Chief Commercial Officer
Press Release: MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer
MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announc
With 45% Ownership, MiMedx Group, Inc. (NASDAQ:MDXG) Has Piqued the Interest of Institutional Investors
Wound Skin Substitutes Market Global Analysis to 2030, Featuring Coloplast, Smith & Nephew, MTF Biologics, MiMedx, AlloSource, Organogenesis, RTI Surgical, LifeNet Health and Molecular Biologicals
Wound Biologics Market Global Analysis and Forecast to 2030, Featuring Profiles of AlloSource, LifeNet Health, Smith & Nephew, Sanara MedTech, Mtf Biologics, Becton, Dickinson, MiMedx and TissueTech
MiMedx Group, Inc.'s (NASDAQ:MDXG) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
It is hard to get excited after looking at MiMedx Group's (NASDAQ:MDXG) recent performance, when its stock has declined 11% over the past three months. But if you pay close attention, you might gath
Craig-Hallum Maintains MiMedx(MDXG.US) With Buy Rating
Craig-Hallum analyst Chase Knickerbocker maintains $MiMedx(MDXG.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 45.9% and a total average return of 2.1% over the p
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the following
We Believe MiMedx Group's (NASDAQ:MDXG) Earnings Are A Poor Guide For Its Profitability
MiMedx Group, Inc.'s (NASDAQ:MDXG) stock rose after it released a robust earnings report. While the headline numbers were strong, we found some underlying problems once we started looking at what dro
The 20% Return This Week Takes MiMedx Group's (NASDAQ:MDXG) Shareholders Five-year Gains to 148%
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But when you pick a company that is really flourishing, you can make more tha
Buy Rating Affirmed for MiMedx on Strong Performance and Favorable Market Outlook
MiMedx Group Up Over 18%, On Track for Largest Percent Increase Since May 2023 -- Data Talk
MiMedx Group, Inc. (MDXG) is currently at $7.28, up $1.12 or 18.18% --Would be highest close since April 1, 2024, when it closed at $7.45 --On pace for largest percent increase since May 3, 2023, wh
Express News | MiMedx Group Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results
Express News | HC Wainwright & Co. Reiterates Buy on MiMedx Group, Maintains $11 Price Target
MiMedx Group Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 67.43% HC Wainwright & Co. → $11 Reiterates Buy → Buy 03/07/2024 82.65% Lake Street → $12 Initi
MiMedx Group: Strong Financial Performance and Future Growth Potential Affirm Buy Rating